The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2017

Filed:

Apr. 10, 2012
Applicants:

Maojian Gu, Pudong District, CN;

Qilan Zheng, Shanghai, CN;

Chao Xu, Fuyang Hangzhou, CN;

Ning LI, Fuyang Hangzhou, CN;

Guixian Chen, Fuyang Hangzhou, CN;

Lan Zheng, Fuyang Hangzhou, CN;

Min Wang, Fuyang Hangzhou, CN;

Lintao Jiang, Fuyang Hangzhou, CN;

Inventors:

Maojian Gu, Pudong District, CN;

Qilan Zheng, Shanghai, CN;

Chao Xu, Fuyang Hangzhou, CN;

Ning Li, Fuyang Hangzhou, CN;

Guixian Chen, Fuyang Hangzhou, CN;

Lan Zheng, Fuyang Hangzhou, CN;

Min Wang, Fuyang Hangzhou, CN;

Lintao Jiang, Fuyang Hangzhou, CN;

Assignee:

Zhejiang Hisun Pharmaceutical Co., Ltd., Jiaojang District, Taizhou, Zhejiang, CN;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/28 (2006.01); A61K 31/133 (2006.01); A61K 31/4965 (2006.01); A61K 31/496 (2006.01); A61K 31/4409 (2006.01); A61K 9/20 (2006.01); A61K 9/24 (2006.01);
U.S. Cl.
CPC ...
A61K 9/286 (2013.01); A61K 9/209 (2013.01); A61K 9/2086 (2013.01); A61K 9/28 (2013.01); A61K 9/284 (2013.01); A61K 9/2866 (2013.01); A61K 9/2886 (2013.01); A61K 31/133 (2013.01); A61K 31/4409 (2013.01); A61K 31/496 (2013.01); A61K 31/4965 (2013.01);
Abstract

Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.


Find Patent Forward Citations

Loading…